The objective of this study is to investigate whether JNJ-40411813 versus placebo reduces
psychosis-like symptoms, induced by infusion of a low dose of ketamine. Effects of
JNJ-40411813 on ketamine-induced symptoms will be evaluated about 3 hours after a single oral
dose when the concentration of JNJ-40411813 in the blood is at its maximum and up to 24 hours
after dose administration to assess the duration of a potential JNJ-40411813 effect.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.